Insider sales are trivial relative to market cap and follow typical post-vesting patterns. No bearish signal. Monitor next earnings (likely late June) for any fundamental changes; this cluster alone does not warrant action.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $16.81entry
- T+1 · 7mo ago +0.71%α +1.08% · $16.93
- T+5 · 6mo ago −1.73%α −4.08% · $16.52
- T+20 · 6mo ago +3.45%α −1.81% · $17.39
- T+60 · 4mo ago +40.39%α +38.91% · $23.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three C-suite insiders at Nurix Therapeutics sold a total of $415K in open-market shares over a 7-day window, with the CFO and Chief Legal Officer accounting for the bulk of the sales. The cluster represents ~0.02% of the $1.8B market cap, which is trivial in proportion and likely reflects routine portfolio diversification or tax planning rather than a negative signal on fundamentals.
Key Financial Metrics
Key Facts
- CFO Hans van Houte sold $263K (13,473 shares at $16.58) on May 5 and April 30
- Chief Legal Officer Christine Ring sold $282K (8,148 shares at $16.96) on May 4 and April 30
- Chief Scientific Officer Gwenn Hansen sold $53K (3,214 shares at $16.65) on April 30
- Total open-market sales: $598K across 3 insiders; non-cash derivative exercises (6,000 shares at $0) have no economic impact
- Sales represent ~0.03% of NRIX's $1.8B market cap, well below the 0.1% materiality threshold
- All sales occurred at prices near $16.60, within the stock's recent range; no clustering at a peak
Financial Impact
$598K in total open-market sales, ~0.03% of market cap, immaterial
Risk Factors
- Insider sales could accelerate if upcoming clinical data disappoints
- Stock is in a volatile biotech sector; any negative catalyst could amplify selling
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NRIX-1778025250503 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers